

REMARKS/ARGUMENTS

Claims 92-123 are pending in this application.

In response to the restriction requirement, Applicants hereby elect the following species: Arg³³, Leu²⁰, Gln³⁴, Lys¹⁸ (N^ε-(γ-aminobutyroyl(N^α-hexadecanoyl))) exendin-4-(7-45)-NH₂.


The pending claims readable on this species are claims 92-94, 96-99, 104-106 and 121-123

Applicants hereby reserve the right to file continuing applications directed to the nonelected subject matter.

The Examiner is hereby invited to contact the undersigned by telephone if there are any questions concerning this response or application.

Respectfully submitted,

Date: January 22, 2004


Richard W. Bork, Reg. No. 36,459
Novo Nordisk Pharmaceuticals, Inc.
100 College Road West
Princeton, NJ 08540
(609) 987-5800

Use the following customer number for all correspondence regarding this application.

23650

PATENT TRADEMARK OFFICE